Imbalanced circulating matrix metalloproteinases in polycystic ovary syndrome

Molecular and Cellular Biochemistry

Volumn 353, Issue 1-2, 2011, Pages 251-257

  Gomes, Valéria A ^a   Vieira, Carolina S ^b,c   Jacob Ferreira, Anna L ^a   Belo, Vanessa A ^a   Soares, Gustavo M ^b   Fernandes, Janaína B F ^b   Ferriani, Rui A ^b,c   Tanus Santos, Jose E ^b  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c National Institute of Hormones and Women's Health   (Brazil)

Author keywords

Hyperandrogenism; Metalloproteinases; Polycystic ovary syndrome; Tissue inhibitors of metalloproteinases

Indexed keywords

GELATIN; GELATINASE A; GELATINASE B; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEUTROPHIL COLLAGENASE; TESTOSTERONE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE MARKER; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERANDROGENISM; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; OVARY POLYCYSTIC DISEASE; PREDICTION; TRIACYLGLYCEROL BLOOD LEVEL; ZYMOGRAPHY;

ANALYSIS OF VARIANCE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 8; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; POLYCYSTIC OVARY SYNDROME; TESTOSTERONE; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TISSUE INHIBITOR OF METALLOPROTEINASES; YOUNG ADULT;

EID: 79959247739     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-011-0793-6     Document Type: Article

References (42)

1. Carmina E, Lobo RA (1999) Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab 84(6): 1897-1899 (Pubitemid 30647006)
2. Group. TREA-SPCW (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81(1):19-25
3. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE (2005) Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 90(4): 1929-1935 (Pubitemid 40586223)
4. Legro RS, Kunselman AR, Dodson WC, Dunaif A (1999) Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84(1):165-169 (Pubitemid 29036695)
5. Norman RJ (2001) Obesity, polycystic ovary syndrome and anovulation-how are they interrelated? Curr Opin Obstet Gynecol 13(3):323-327
6. Norman RJ, Masters S, Hague W (1996) Hyperinsulinemia is common in family members of women with polycystic ovary syndrome. Fertil Steril 66(6):942-947 (Pubitemid 26423677)
7. Diamanti-Kandarakis E, Alexandraki K, Piperi C, Protogerou A, Katsikis I, Paterakis T, Lekakis J, Panidis D (2006) Inflammatory and endothelial markers in women with polycystic ovary syndrome. Eur J Clin Invest 36(10):691-697 (Pubitemid 44393927)
8. Heutling D, Schulz H, Nickel I, Kleinstein J, Kaltwasser P, Westphal S, Mittermayer F, Wolzt M, Krzyzanowska K, Randeva H, Schernthaner G, Lehnert H (2008) Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment. J Clin Endocrinol Metab 93(1):82-90
9. Gonzalez F, Rote NS, Minium J, Kirwan JP (2009) Evidence of proatherogenic inflammation in polycystic ovary syndrome. Metabolism 58(7):954-962
10. Vural B, Caliskan E, Turkoz E, Kilic T, Demirci A (2005) Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome. Hum Reprod 20(9):2409-2413 (Pubitemid 41222485)
11. Orio F Jr, Palomba S, Cascella T, De Simone B, Di Biase S, Russo T, Labella D, Zullo F, Lombardi G, Colao A (2004) Early impairment of endothelial structure and function in young normal- weight women with polycystic ovary syndrome. J Clin Endocrinol Metab 89(9):4588-4593 (Pubitemid 39244474)
12. Lakhani K, Seifalian AM, Hardiman P (2002) Impaired carotid viscoelastic properties in women with polycystic ovaries. Circulation 106(1):81-85 (Pubitemid 34747446)
13. Soares GM, Vieira CS, Martins WP, Franceschini SA, dos Reis RM, Silva de Sa MF, Ferriani RA (2009) Increased arterial stiffness in nonobese women with polycystic ovary syndrome (PCOS) without comorbidities: one more characteristic inherent to the syndrome? Clin Endocrinol (Oxf) 71(3):406-411
14. Sapienza P, di Marzo L, Borrelli V, Sterpetti AV, Mingoli A, Cresti S, Cavallaro A (2005) Metalloproteinases and their inhibitors are markers of plaque instability. Surgery 137(3): 355-363 (Pubitemid 40312215)
15. Johnson JL, Jackson CL, Angelini GD, George SJ (1998) Activation of matrix-degrading metalloproteinases by mast cell proteases in atherosclerotic plaques. Arterioscler Thromb Vasc Biol 18(11):1707-1715 (Pubitemid 28521059)
16. Formato M, Farina M, Spirito R, Maggioni M, Guarino A, Cherchi GM, Biglioli P, Edelstein C, Scanu AM (2004) Evidence for a proinflammatory and proteolytic environment in plaques from endarterectomy segments of human carotid arteries. Arterioscler Thromb Vasc Biol 24(1):129-135 (Pubitemid 38082423)
17. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, Meyer J, Cambien F, Tiret L (2003) Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 107(12):1579-1585 (Pubitemid 36397324)
18. Creemers EE, Cleutjens JP, Smits JF, Daemen MJ, van den Borne SW, Hanemaaijer R, Blankesteijn WM (2001) Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Increased matrix metalloproteinase- 8 and -9 activity in patients with infarct rupture after myocardial infarction. Circ Res 89(3):201-210
19. Fatar M, Stroick M, Griebe M, Hennerici M, Creemers EE, Cleutjens JP, Smits JF, Daemen MJ, van den Borne SW, Hanemaaijer R, Blankesteijn WM (2005) Matrix metalloproteinases in cerebrovascular diseases Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Increased matrix metalloproteinase-8 and -9 activity in patients with infarct rupture after myocardial infarction. Cerebrovasc Dis 20(3):141-151
20. van den Borne SW, Cleutjens JP, Hanemaaijer R, Creemers EE, Smits JF, Daemen MJ, Blankesteijn WM (2009) Increased matrix metalloproteinase-8 and -9 activity in patients with infarct rupture after myocardial infarction. Cardiovasc Pathol 18(1):37-43
21. Molloy KJ, Thompson MM, Jones JL, Schwalbe EC, Bell PR, Naylor AR, Loftus IM (2004) Unstable carotid plaques exhibit raised matrix metalloproteinase-8 activity. Circulation 110(3): 337-343 (Pubitemid 38955503)
22. Tuomainen AM, Nyyssonen K, Laukkanen JA, Tervahartiala T, Tuomainen TP, Salonen JT, Sorsa T, Pussinen PJ (2007) Serum matrix metalloproteinase-8 concentrations are associated with cardiovascular outcome in men. Arterioscler Thromb Vasc Biol 27(12):2722-2728 (Pubitemid 350158928)
23. Laxton RC, Hu Y, Duchene J, Zhang F, Zhang Z, Leung KY, Xiao Q, Scotland RS, Hodgkinson CP, Smith K, Willeit J, Lopez- Otin C, Simpson IA, Kiechl S, Ahluwalia A, Xu Q, Ye S (2009) A role of matrix metalloproteinase-8 in atherosclerosis. Circ Res 105(9):921-929
24. Goncalves FM, Jacob-Ferreira AL, Gomes VA, Casella-Filho A, Chagas AC, Marcaccini AM, Gerlach RF, Tanus-Santos JE (2009) Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome. Clin Chim Acta 403(1-2):173-177
25. Belo VA, Souza-Costa DC, Lana CM, Caputo FL, Marcaccini AM, Gerlach RF, Bastos MG, Tanus-Santos JE (2009) Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents. Clin Biochem 42(10-11):984-990
26. Palei AC, Sandrim VC, Cavalli RC, Tanus-Santos JE (2008) Comparative assessment of matrix metalloproteinase (MMP)-2 and MMP-9, and their inhibitors, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in preeclampsia and gestational hypertension. Clin Biochem 41(10-11):875-880
27. Liu B, Cai LY, Lv HM, Xia L, Zhang YJ, Zhang HX, Guan YM (2008) Raised serum levels of matrix metalloproteinase-9 in women with polycystic ovary syndrome and its association with insulin-like growth factor binding protein-1. Gynecol Endocrinol 24(5):285-288 (Pubitemid 351891659)
28. Diamanti-Kandarakis E, Livadas S, Kandarakis SA, Margeli A, Papassotiriou I (2008) Serum concentrations of atherogenic proteins neutrophil gelatinase-associated lipocalin and its complex with matrix metalloproteinase-9 are significantly lower in women with polycystic ovary syndrome: hint of a protective mechanism? Eur J Endocrinol 158(4):525-531 (Pubitemid 351606348)
29. Lewandowski KC, Komorowski J, O'Callaghan CJ, Tan BK, Chen J, Prelevic GM, Randeva HS (2006) Increased circulating levels of matrix metalloproteinase-2 and -9 in women with the polycystic ovary syndrome. J Clin Endocrinol Metab 91(3): 1173-1177 (Pubitemid 43357797)
30. Raffetto JD, Khalil RA (2008) Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol 75(2):346-359 (Pubitemid 350298459)
31. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19(1):41-47
32. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18(6):499-502
33. Mathur RS, Moody LO, Landgrebe S, Williamson HO (1981) Plasma androgens and sex hormone-binding globulin in the evaluation of hirsute females. Fertil Steril 35(1):29-35 (Pubitemid 11168911)
34. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412-419 (Pubitemid 15018832)
35. Souza-Tarla CD, Uzuelli JA, Machado AA, Gerlach RF, Tanus-Santos JE (2005) Methodological issues affecting the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Clin Biochem 38(5):410-414
36. Gerlach RF, Uzuelli JA, Souza-Tarla CD, Tanus-Santos JE (2005) Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Anal Biochem 344(1):147-149 (Pubitemid 41569391)
37. Gerlach RF, Demacq C, Jung K, Tanus-Santos JE (2007) Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma. Clin Biochem 40(1-2):119-123 (Pubitemid 46014168)
38. Worley JR, Thompkins PB, Lee MH, Hutton M, Soloway P, Edwards DR, Murphy G, Knauper V (2003) Sequence motifs of tissue inhibitor of metalloproteinases 2 (TIMP-2) determining progelatinase A (proMMP-2) binding and activation by membrane- type metalloproteinase 1 (MT1-MMP). Biochem J 372(Pt 3):799-809 (Pubitemid 36760393)
39. Cowell S, Knauper V, Stewart ML, D'Ortho MP, Stanton H, Hembry RM, Lopez-Otin C, Reynolds JJ, Murphy G (1998) Induction of matrix metalloproteinase activation cascades based on membrane-type 1 matrix metalloproteinase: associated activation of gelatinase A, gelatinase B and collagenase 3. Biochem J 331(Pt 2):453-458 (Pubitemid 28182159)
40. Norman RJ, Dewailly D, Legro RS, Hickey TE (2007) Polycystic ovary syndrome. Lancet 370(9588):685-697 (Pubitemid 47285318)
41. Carmina E, Chu MC, Longo RA, Rini GB, Lobo RA, Luque- Ramirez M, Mendieta-Azcona C, Alvarez-Blasco F, Escobar- Morreale HF (2005) Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters. J Clin Endocrinol Metab 90(5): 2545-2549 (Pubitemid 40686289)
42. Luque-Ramirez M, Mendieta-Azcona C, Alvarez-Blasco F, Escobar-Morreale HF (2007) Androgen excess is associated with the increased carotid intima-media thickness observed in young women with polycystic ovary syndrome. Hum Reprod 22(12): 3197-3203 (Pubitemid 351696785)